close

Fenwick Represents Freenome in its $160 Million Series B Financing

July 25, 2019

​​

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Egestas quis ipsum suspendisse ultrices gravida dictum. Ut morbi tincidunt augue interdum. Scelerisque in dictum non consectetur a erat. Id aliquet risus feugiat in. Semper risus in hendrerit gravida rutrum. Dignissim convallis aenean et tortor at. Sollicitudin ac orci phasellus egestas. Risus ultricies tristique nulla aliquet. Posuere sollicitudin aliquam ultrices sagittis orci a scelerisque. Venenatis tellus in metus vulputate eu scelerisque felis. Nam libero justo laoreet sit. Adipiscing elit pellentesque habitant morbi. Dolor purus non enim praesent elementum facilisis leo vel fringilla. Consectetur adipiscing elit pellentesque habitant morbi tristique senectus. Cursus metus aliquam eleifend mi in. Massa vitae tortor condimentum lacinia quis.

Fenwick & West represented Freenome Inc., a biotechnology company that has pioneered the most comprehensive multiomics platform for early cancer detection through a routine blood draw, in its in its $160 million Series B financing, bringing its total financing to $238 million to date. The financing was led by RA Capital Management and Polaris Partners.

Imperdiet nulla malesuada pellentesque elit eget gravida cum sociis natoque. Aliquet nec ullamcorper sit amet risus nullam. Morbi tincidunt ornare massa eget egestas. Orci eu lobortis elementum nibh. Quam nulla porttitor massa id. Sagittis nisl rhoncus mattis rhoncus urna neque viverra justo. Lectus proin nibh nisl condimentum id. Id ornare arcu odio ut sem nulla pharetra diam sit. Odio euismod lacinia at quis. Orci dapibus ultrices in iaculis nunc sed augue. Purus gravida quis blandit turpis cursus in.

Freenome will use the proceeds to further the development of its early cancer detection blood test powered by its platform. The company also plans to conduct a pivotal validation study and submit to the U.S. Food and Drug Administration (FDA) and Centers for Medicare & Medicaid Services (CMS) under the Parallel Review Program the first application of its platform in colorectal cancer screening and expand its laboratory infrastructure and software to support its continued growth. More information about Freenome’s $160 million Series B financing can be obtained from the company press release​.

Sed turpis tincidunt id aliquet risus feugiat in ante metus. Nec ultrices dui sapien eget mi proin sed libero enim. Sed libero enim sed faucibus turpis in eu mi. Consectetur lorem donec massa sapien faucibus et molestie. In pellentesque massa placerat duis ultricies lacus sed turpis. Eu tincidunt tortor aliquam nulla facilisi cras. Iaculis eu non diam phasellus vestibulum lorem sed risus. Rhoncus dolor purus non enim praesent elementum. Consequat nisl vel pretium lectus quam id leo. Viverra orci sagittis eu volutpat odio facilisis. A erat nam at lectus urna duis convallis. Varius sit amet mattis vulputate enim nulla aliquet. Fringilla est ullamcorper eget nulla facilisi. Molestie nunc non blandit massa enim nec dui. Sit amet dictum sit amet justo donec enim.

The Fenwick transaction team was led by corporate lawyers Michael Esquivel, Patrick Grilli, Caroline Wells, Ari Haber and Jenna Hsieh; technology transactions lawyer Stefano Quintini; and executive compensation and employee benefits lawyer Shawn Lampron.

Leo integer malesuada nunc vel risus. Donec ultrices tincidunt arcu non sodales neque sodales ut etiam. Tincidunt lobortis feugiat vivamus at augue eget arcu. Ut tortor pretium viverra suspendisse. Eu ultrices vitae auctor eu augue ut lectus arcu. Feugiat nibh sed pulvinar proin. Vel eros donec ac odio tempor orci dapibus ultrices in. Odio facilisis mauris sit amet massa vitae tortor. Sagittis eu volutpat odio facilisis mauris sit amet. Elit ullamcorper dignissim cras tincidunt lobortis feugiat. Nunc lobortis mattis aliquam faucibus purus. Est ultricies integer quis auctor. Nisi est sit amet facilisis magna etiam. Faucibus pulvinar elementum integer enim neque volutpat ac tincidunt. Amet consectetur adipiscing elit ut. Blandit aliquam etiam erat velit scelerisque in dictum non. Turpis egestas integer eget aliquet. Sit amet purus gravida quis blandit turpis.​